Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism in patients with chronic renal failure undergoing haemodialysis.

Paricalcitol is a synthetic, biologically active vitamin D analog of calcitriol with modifications to the side chain (D2) and the A (19-nor) ring allowing for selective vitamin D receptor (VDR) activation.Paricalcitol also upregulates the calcium sensing receptor (CaSR) in the parathyroid glands.

As a result, paricalcitol reduces parathyroid hormone (PTH) levels by inhibiting parathyroid proliferation.

Active ingredient Pharmaceutical form Package Therapeutic target
  • Paricalcitol
  • Sol. for Injection
  • 5mcg/ml
  • 10mcg/2ml
  • 2mcg/ml
  • 4mcg/2ml 
  • Hyperparathyroidism(Patients with Chronic Renal Failure on Haemodialysis )

Other products in "International"